Literature DB >> 15287080

A general statistical principle for changing a design any time during the course of a trial.

Hans-Helge Müller1, Helmut Schäfer.   

Abstract

A general method is presented that allows the researcher to change statistical design elements such as the residual sample size during the course of an experiment, to include an interim analysis for early stopping when no formal rule for early stopping was foreseen, to increase or reduce the number of planned interim analyses, to change time points and the type I error spending function for the further design of interim analyses, or to change the test statistic, the outcome measure, etc. At the time of a pre-planned interim analysis for early stopping or at any time of an interim look without spending part of the type I error level the method offers the option to completely redesign the remaining part of the trial, without affecting the type I error level. The method is described in the usual Brownian motion model and extended to the general context of statistical decision functions. It is based on the conditional rejection probability of a decision variable.

Mesh:

Substances:

Year:  2004        PMID: 15287080     DOI: 10.1002/sim.1852

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  28 in total

1.  Longitudinal clinical trials with adaptive choice of follow-up time.

Authors:  Neal Jeffries; Nancy L Geller
Journal:  Biometrics       Date:  2015-03-27       Impact factor: 2.571

2.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

3.  Adaptive Budgets in Clinical Trials.

Authors:  Martin Posch; Peter Bauer
Journal:  Stat Biopharm Res       Date:  2013-04-04       Impact factor: 1.452

4.  Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.

Authors:  Alexandra C Graf; Peter Bauer
Journal:  Stat Med       Date:  2011-04-15       Impact factor: 2.373

5.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

6.  Unplanned adaptations before breaking the blind.

Authors:  Martin Posch; Michael A Proschan
Journal:  Stat Med       Date:  2012-06-27       Impact factor: 2.373

7.  Planning future studies based on the conditional power of a meta-analysis.

Authors:  Verena Roloff; Julian P T Higgins; Alex J Sutton
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

8.  Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933].

Authors:  Francisco Martinez-Torres; Sanjay Menon; Maria Pritsch; Norbert Victor; Ekkehart Jenetzky; Katrin Jensen; Eva Schielke; Erich Schmutzhard; Jan de Gans; Chin-Hee Chung; Steffen Luntz; Werner Hacke; Uta Meyding-Lamadé
Journal:  BMC Neurol       Date:  2008-10-29       Impact factor: 2.474

9.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs.

Authors:  D Magirr; T Jaki; M Posch; F Klinglmueller
Journal:  Biometrika       Date:  2013-12-01       Impact factor: 2.445

10.  Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.

Authors:  Nicolás M Ballarini; Thomas Burnett; Thomas Jaki; Christoper Jennison; Franz König; Martin Posch
Journal:  Stat Med       Date:  2021-03-29       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.